Special Issue "Poor-Risk and Relapsed/Refractory Germ Cell Tumor"
Deadline for manuscript submissions: 31 January 2022.
Germ cell tumors (GCT) belong to the most chemosensitive solid tumors and represent a model for a curable cancer. Cisplatin represents the mainstay in the treatment of GCTs. Cisplatin-based first line chemotherapy can cure about 70–80% of patients with disseminated testicular cancer. Salvage chemotherapy with standard dose cisplatin plus previously not utilized drugs will cure 20–25% of patients who were not initially cured with their induction chemotherapy.
Because of insufficient results in the treatment of poor-risk and relapsed/refractory GCTs, evaluation of new treatment strategies and new drugs with significant antitumor activity, as single-agent or combination treatments, remains a priority. Identification of new biomarkers and/or therapeutic targets remains one of the research goals as well.
This Special issue of IJMS is focused on advances in research of poor-risk and relapsed/refractory testicular germ cell tumor and articles that cover this topic, including preclinical research, biomarker research, and research that focuses on special subpopulations of patients are welcome.
Prof. Michal Mego
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- testicular germ cell tumors
- multiple relapsed/refractory
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Planned paper 1: Growing teratoma syndrome in the setting of post-chemotherapy testicular germ cell tumors
Planned paper 2: High-dose chemotherapy, an unsurpassed frontier of salvage treatment for relapsed germ-cell tumors